Publications by authors named "Kysa Meek"

Claim this Profile
A
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Elizabeth Fox, John M Maris, Brigitte C Widemann, Kysa Meek, Anne Goodwin

Clin Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Kenneth R Hande, Anne Hagey, Jordan Berlin, Yingna Cai, Kysa Meek

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis